Cancer vaccine therapy using epitope peptide from KIF20A restricted to HLA-A*24 in patients with pancreatic cancer refractory to standard therapy (Phase I/II study)
Phase 1
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000004919
- Lead Sponsor
- Chiba Tokushukai Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1.Pregnancy 2.Lactation 3.Patients having will of pregnancy. 4.Patients have uncontrollable severe infectional diseases. 5.Patients who are treated with steroid or immunotherapy during clinical trial. 6.Patients have uncontrollable associated cancer. 7.Patients who have non-recovered injury. 8.Patients judged inappropriated by doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Safety and adverse effect 2.Antitumor effect
- Secondary Outcome Measures
Name Time Method 1.Immunological response Peptide specific CTL response in vitro Antigen cascade 2.Clinical efficacy Overall survival Progression free survival Median survival time